Cell & Gene Therapies

(Image: Getty/gradyreese)

Nightstar acquired by Biogen for $800m

By Maggie Lynch

Biogen agrees Nightstar acquisition for $800m to take on its pipeline of AAV treatments for retinal disorders, diversifyingy its pipeline in the rare disease market.

(Image: Getty/Dr_Microbe)

Cell therapy market to triple in size by 2025

By Ben Hargreaves

The market for cell therapy products is set to expand based on increasing investment from the industry and the implementation of advanced manufacturing technologies.

(Image: Getty/Phototechno)

How to solve a problem like Kymriah

By Ben Hargreaves

In its full-year financials, Novartis announced plans to transform its cell therapy manufacturing process through greater investment and utilisation of digital technologies.

Follow us

Products

View more

Webinars